Xevinapant Five-Year Data Show Survival Rate Nearly Doubled in Patients with Unresected LA SCCHN, When Added to Standard of Care

• First randomized trial in a long time to present important enchancment in total survival in sufferers with LA SCCHN, reinforcing the transformative potential of xevinapant over commonplace of care in the healing setting
• Patients handled with xevinapant plus CRT nearly twice as doubtless to be alive at 5 years (53% vs 28%) in Phase II research
• Two ongoing Phase III scientific trials of xevinapant in this setting, TrilynX and XRay Vision, are presently recruiting, with greater than 250 facilities worldwide

​

Merck, a number one science and expertise firm, right now introduced that the IAP (inhibitor of apoptosis protein) inhibitor xevinapant (previously referred to as Debio 1143) plus chemoradiotherapy (CRT) markedly improved long-term efficacy outcomes in sufferers with unresected regionally superior squamous cell carcinoma of the top and neck (LA SCCHN) in contrast with placebo plus CRT. The addition of xevinapant greater than halved the danger of demise over 5 years in contrast with placebo. These late-breaking knowledge from the 96-patient Phase II trial will probably be introduced through the mini-oral session on head and neck most cancers on September 10, 2022 at 10:55 AM CEST (Abstract #LBA33) on the European Society of Medical Oncology Congress 2022.

“There is a clear need for improved treatment options for patients with unresected locally advanced head and neck cancer. Chemoradiotherapy has served as the standard of care in this setting for the past several decades, yet half of patients treated with CRT see their cancer return, whether locally or as metastatic disease,” mentioned Prof. Jean Bourhis, M.D., Ph.D., Department Head of Radio-Oncology on the University Hospital of Lausanne and lead investigator of the research. “The five-year results from this randomized Phase II study are the first to show improved efficacy outcomes over standard of care for these patients and suggest the potential for xevinapant to increase the proportion of patients who achieve cure following definitive therapy.”

In this evaluation, total survival (OS) was evaluated at 5 years after the final affected person was randomized; median follow-up was 60.1 months (vary, 7.1-70.5 months) in the xevinapant arm and 39.2 months (vary, 4.8-71.2 months) in the placebo arm. The knowledge present:

• Xevinapant greater than halved the danger of demise over 5 years of follow-up in contrast with placebo (adjusted HR, 0.47 [95% CI, 0.27-0.84]; nominal p=0.0101).
• Median OS was extended with xevinapant (median not reached; 95% CI, 40.3 months-not evaluable) versus placebo (36.1 months; 95% CI, 21.8-46.7 months).

• Treatment with xevinapant practically doubled OS, with a 53% (95% CI, 37-66%) chance of survival after 5 years in contrast with 28% (95% CI, 15-42%) with placebo.

As beforehand reported, the addition of xevinapant to CRT was well-tolerated and constant with the security profile of CRT alone with roughly two years of follow-up. Adverse occasions of grade 3 or larger have been reported in 41 (85%) of 48 sufferers in the xevinapant group and 41 (87%) of 47 sufferers in the placebo group. The commonest grade 3 or larger treatment-emergent hostile occasions amongst sufferers who acquired xevinapant plus CRT that occurred in greater than 15% of sufferers have been dysphagia (50%), anemia (35%), mucositis (31%), and neutropenia (23%).¹ Follow-up evaluation at three years confirmed related security.²

“Head and neck cancer is a devastating disease that often has a profound impact on a patient’s ability to eat, communicate and even sleep, yet there have been few treatment advances over the past 20 years,” mentioned Amanda Hollinger, Executive Director, Head and Neck Cancer Alliance. “We are hopeful that these findings may pave the way for a new approach that can improve outcomes.”

Previously reported outcomes from the randomized, double-blind Phase II research confirmed the addition of xevinapant to standard-of-care CRT offered a statistically important enchancment in locoregional management fee at 18 months, the first endpoint, versus placebo and CRT in sufferers with unresected LA SCCHN (54% [95% CI, 39 to 69] versus 33% [95% CI, 20 to 48]; odds ratio 2.69 [95% CI, 1.13 to 6.42]; p=0.026). Primary outcomes of the research have been revealed in The Lancet Oncology.¹

“The opportunity to develop an oncology medicine in a curative setting is a rare privilege, especially for a hard-to-treat disease such as locally advanced head and neck cancer, where many patients cannot undergo surgery,” mentioned Victoria Zazulina, M.D., Head of Development Unit Oncology, Merck. “Based on these Phase II results, we are committed to exploring the potential value of xevinapant in the locally advanced setting through our ongoing Phase III program, as we pioneer the investigation of the apoptotic pathway as a novel treatment modality.”

Based on the promising efficacy and security profile seen in the Phase II trial, and the pressing want for brand new therapies, xevinapant is being evaluated in two ongoing Phase III scientific trials. The first is the worldwide, randomized, double-blind, placebo-controlled TrilynX research (NCT04459715) to consider the efficacy and security of xevinapant versus placebo when added to definitive CRT in sufferers with unresected LA SCCHN. The second is XRay Vision (NCT05386550), a randomized, double-blind, placebo-controlled research to consider the efficacy and security of xevinapant versus placebo when added to adjuvant, post-operative radiotherapy in sufferers with resected LA SCCHN who’re at excessive threat for relapse and are ineligible for cisplatin. Both TrilynX and XRay Vision are presently recruiting.

In February 2020, the U.S. Food and Drug Administration granted Breakthrough Therapy Designation to xevinapant (previously beneath improvement with Debiopharm as Debio 1143) for therapy of sufferers with beforehand untreated LA SCCHN, in mixture with present commonplace of care, based mostly on outcomes of the Phase II trial.

About Head and Neck Cancer

Worldwide, head and neck most cancers accounts for greater than 870,000 instances and 440,000 deaths yearly,³ making it the eighth commonest most cancers sort. LA SCCHN is a extremely debilitating illness that may lead to impaired respiration, swallowing, and speech because it progresses. Despite therapy with healing intent utilizing standard-of-care CRT, roughly 50% of sufferers with LA SCCHN develop native recurrence and/or distant metastasis,⁴ that are often detected throughout the first two years after completion of standard-of-care therapy, underscoring the necessity to determine new therapeutic approaches.

About Xevinapant

Xevinapant (previously referred to as Debio 1143) is an investigational first-in-class potent oral small-molecule IAP (inhibitor of apoptosis protein) inhibitor for the therapy of LA SCCHN. In preclinical research, xevinapant restored sensitivity to apoptosis in most cancers cells, thereby enhancing the results of chemotherapy and radiotherapy. Xevinapant, probably the most clinically superior IAP inhibitor, improved efficacy outcomes in mixture with chemoradiotherapy (CRT), together with three-year progression-free survival and five-year survival, in contrast with placebo plus CRT in a Phase II research in sufferers with unresected LA SCCHN. In March 2021, Merck, gained unique rights from Debiopharm to develop and commercialize xevinapant worldwide. Xevinapant will not be accepted for any use anyplace in the world.

All Merck Press Releases are distributed by e-mail on the identical time they turn out to be accessible on the Merck Website. Please go to www.merckgroup.com/subscribe to register on-line, change your choice or discontinue this service.

About Merck

Merck, a number one science and expertise firm, operates throughout life science, healthcare and electronics. More than 60,000 workers work to make a optimistic distinction to thousands and thousands of folks’s lives every single day by creating extra joyful and sustainable methods to dwell. From advancing gene enhancing applied sciences and discovering distinctive methods to deal with probably the most difficult ailments to enabling the intelligence of gadgets – the corporate is in every single place. In 2021, Merck generated gross sales of € 19.7 billion in 66 international locations.

Scientific exploration and accountable entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding household stays the bulk proprietor of the publicly listed firm. Merck holds the worldwide rights to the Merck identify and model. The solely exceptions are the United States and Canada, the place the business sectors of Merck function as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.

View supply model on businesswire.com: https://www.businesswire.com/news/home/20220906005035/en/